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SUMMARY 
During early embryogenesis pluripotent cells of the inner cell mass (ICM) give 
rise to a second pluripotent cell population known as the primitive ectoderm an 
obligate developmental intermediate and the substrate for gastrulation. The ICM 
and primitive ectoderm are distinguished on the basis of morphology, gene 
expression and differentiation potential. However, the signals and mechanisms 
involved in the transition form ICM to primitive ectoderm are not understood. 
Culture of ES cells in the presence of a conditioned medium MEDII leads to a 
transition of ES cells to a population of pluripotent primitive ectoderm-like (EPL) 
cells that are the in vitro equivalent of the primitive ectoderm. In terms of EPL 
cell formation the bioactive component of MEDII was identified as L-proline. In 
this thesis the molecular mechanism by which L-proline induces EPL-cell 
formation was elucidated. 
As well as L-proline, short L-proline containing peptides were also shown to 
induce EPL-cell formation but different peptides displayed different abilities to 
induce the transition with some inducing the complete transition and others 
inducing morphology changes only. The mechanism of L-proline induced EPL­
cell formation was shown to be independent of NK receptors. The mechanism 
of L-proline induced EPL-cell formation, as deduced from the results presented in 
this thesis, was suggested to involve the internalisation of L-proline via the SAT2 
amino acid transporter into ES cells as competitive inhibitors of SAT2 prevented 
EPL-cell formation. MAPK signalling via the action of MEK1 was implicated in L­
proline induced EPL-cell formation as inhibitors of MEK1 prevented EPL-cell 
morphology, gene expression and differentiation potential in the presence of L­
proline. 
PI3K signalling was implicated in L-proline-induced EPL-cell morphology since 
PI3K inhibitor L Y294002 maintained domed colonies in the presence of L-proline 
but failed to maintain an ES-cell gene expression profile and differentiation 
potential. Both MAPK and PI3K signalling were suggested to lie down-stream of 
L-proline action since treatment of ES cells with L-proline induced the activation 
of ERK1/2 and Akt down-stream effectors of MAPK and PI3K signalling 
respectively. A gene potentially involved in the Pl3K-rnediated rnorphology 
change was Lefty2. Therefore, the mechanism of L-proline induced EPL-cell 
formation appears to involve internalisation of L-proline and at least two signalling 
pathways down-stream of L-proline, which regulate different components of the 
transition. 
